Overview

Edaravone on the Ischemia-Reperfusion(I/R) Injury in Kidney Transplantation Patients

Status:
Unknown status
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
Ischemia-reperfusion (I/R) injury is a prominent cause of delayed graft function(DGF) after kidney transplantation. Reactive oxygen species play a crucial role in I/R injury. Edaravone is a synthetic radical scavenger that has been used in acute stroke. Some animal experiments have revealed its beneficial effects against I/R injury, our goal is therefore to investigate the effectiveness of a recipient pretreatment with Edaravone at reducing the occurrence of DGF after kidney transplantation.
Phase:
N/A
Details
Lead Sponsor:
Xijing Hospital
Collaborator:
First Affiliated Hospital Xi'an Jiaotong University
Treatments:
Antipyrine
Edaravone
Pharmaceutical Solutions
Phenylmethylpyrazolone